Key Takeaways

China now runs the world's largest oncology clinical trial pipeline — well over a third of all active global oncology trials, with particular depth in CAR-T, bispecific antibodies, and next-generation immunotherapy.

A formal clinical trial is not the same as "experimental treatment" more broadly — trial enrollment (through China's NMPA/ChiCTR-registered studies) is a distinct pathway from Hainan's Boao Lecheng zone, which lets a handful of authorized hospitals use FDA/EMA-approved therapies that aren't yet NMPA-approved in mainland China.

Eligibility is diagnosis- and protocol-specific — trials have their own inclusion/exclusion criteria on top of standard clinical qualification, and no two studies are identical.

Trial costs vary by design — sponsor-covered studies often subsidize the investigational drug itself, but hospitalization, travel, and standard-of-care components are frequently the patient's responsibility; this needs to be confirmed protocol-by-protocol, not assumed.

Experimental treatment carries real uncertainty — early-phase data can be promising without being proof of durable benefit, and informed consent for a trial is a different conversation than consent for an approved therapy.

ChinaCureLink (a Medebound HEALTH company) helps international patients identify open, relevant trials and Boao Lecheng access options, and coordinates the documentation both pathways require.

Introduction

For patients who've exhausted approved options — or whose cancer type simply doesn't have one yet — clinical trials and experimental therapy access are often the next real conversation. China has become one of the most active places in the world to have that conversation, but it's also one of the most commonly misunderstood parts of researching treatment there.

This guide is a deeper look at one piece of our broader Cancer Treatment in China: The Complete Guide for International Patients — specifically, how clinical trials for cancer in China and early-access experimental treatment actually work for someone coming from outside China, what "access" really means in practice, and what to verify before treating any specific claim as settled.

We'll walk through why China's trial landscape has grown so quickly, the two distinct pathways patients often lump together (formal trial enrollment vs. Hainan's early-access zone), what eligibility and cost realistically look like, and the questions worth asking before you commit to either route.

Why China Has Become a Global Hub for Oncology Clinical Trials

A few structural factors explain why China's oncology trial volume has grown so fast:

• Patient volume. China diagnoses roughly 4.8 million new cancer cases annually — more than any other country — which lets trial sponsors recruit and reach statistical endpoints faster than in most Western markets.

• Policy prioritization. Cell and gene therapy was named a strategic biomedical sector in China's 14th Five-Year Plan (2021–2025), which came with streamlined regulatory review for oncology products.

• Domestic biotech capacity. Companies like CARsgen Therapeutics, JW Therapeutics, Legend Biotech, and Gracell Biotechnologies (acquired by AstraZeneca in 2023) have built end-to-end trial and manufacturing infrastructure inside China rather than relying on imported production.

• Registries built for scale. Trials are tracked through the Chinese Clinical Trial Registry (ChiCTR), NMPA's Center for Drug Evaluation platform, and (for internationally sponsored studies) ClinicalTrials.gov — giving both regulators and outside researchers a way to review what's running and what's been published.

A 2024 analysis published in Nature Medicine found China now accounts for over 40% of all active CAR-T clinical trials globally, with a meaningful share investigating solid tumors — gastric, liver, lung, and nasopharyngeal cancers — where trial activity in the US and Europe remains comparatively early-stage. For background on CAR-T access outside of a trial setting, see our CAR-T country comparison guide.

Two Different Pathways

Patients researching "experimental cancer treatment in China" often run into two very different mechanisms and assume they're the same thing. They aren't, and the distinction matters for cost, eligibility, and what protections apply.

	Formal Clinical Trial	Boao Lecheng Early-Access Zone
What it is	A registered research study (ChiCTR/NMPA IND) testing an investigational or not-yet-approved therapy under a defined protocol	A special regulatory zone in Hainan where a limited number of authorized hospitals may use FDA- or EMA-approved drugs/devices that haven't completed NMPA approval yet
Governed by	Study protocol, ethics committee (IRB) approval, informed consent specific to research	Hainan provincial "urgent clinical need" administrative rules, not a research protocol
Purpose	Generate safety/efficacy data toward eventual approval	Give patients faster access to therapies already approved elsewhere, while the manufacturer separately pursues NMPA approval
Typical cost pattern	Investigational drug is often sponsor-covered; supportive care/hospitalization costs vary by study	Patient generally pays for the drug/device and treatment; no research subsidy, though import tariffs and VAT may be waived on qualifying products
Where it happens	Hospitals nationwide that hold trial site status for a given study	Specifically hospitals authorized within the Boao Lecheng zone in Qionghai, Hainan

Some patients are candidates for both, depending on diagnosis and what's actually open at the time. Neither pathway is a fallback with fewer standards than approved treatment — trials still require ethics review and informed consent, and Boao Lecheng products must already carry an overseas regulatory approval (FDA or EMA) before Hainan can authorize their use.

A Note on Solid Tumor CAR-T

One reason "clinical trial" and "CAR-T" get discussed together so often: in 2026, China became the first country to grant regulatory approval to a CAR-T therapy for a solid tumor (Satri-cel/CT041, targeting CLDN18.2-positive gastric and gastroesophageal junction cancer), following trial data developed largely at Chinese centers. Trials investigating further solid-tumor CAR-T constructs — and dual-target, allogeneic ("off-the-shelf"), and bispecific approaches — remain active and are a meaningful reason some patients look at trial enrollment specifically rather than an approved product alone. For blood cancer indications where CAR-T is already commercially approved, see our disease-specific guides for lymphoma, multiple myeloma, and relapsed/refractory leukemia.

What Kinds of Trials Are International Patients Actually Enrolling In?

Active oncology trial activity in China spans the full development pipeline, though not every phase or study accepts international patients:

• Early-phase (Phase I) trials — testing safety and dosing for novel agents, often the least accessible to international patients due to intensive monitoring requirements and narrower eligibility windows

• Later-phase (Phase II/III) trials — testing efficacy against larger patient groups, sometimes with international arms or expanded-access provisions

• Next-generation CAR-T constructs — dual-antigen targeting, allogeneic (donor-derived rather than patient-specific) cells, and solid-tumor programs

• Bispecific antibodies and novel checkpoint inhibitor combinations — an active area given China's large domestic PD-1/PD-L1 pipeline

• Targeted agents for mutation-specific indications — often for patients whose tumor profiling (NGS) identifies a marker not yet matched by an approved drug at home

Whether a specific study accepts international enrollment is decided study-by-study, not as a blanket policy — this is one of the most important things to confirm early rather than assume.

Eligibility: What Determines Whether You Qualify

Trial eligibility works in layers, and clearing the first doesn't guarantee the second:

1. General clinical qualification — similar to standard treatment pathways, most oncology trials require a confirmed diagnosis, adequate organ function, and a documented treatment history (including whether standard options have already been tried and failed).

2. Protocol-specific inclusion/exclusion criteria — each trial defines its own requirements: specific biomarker or antigen status confirmed on pathology, a defined range of prior treatment lines, a specific performance status cutoff, and exclusion of certain comorbidities or concurrent medications.

3. Logistical fit — some protocols require a minimum on-site stay for monitoring that international patients need to plan around realistically, similar to the post-infusion monitoring windows required for commercially approved CAR-T.

Because these criteria are protocol-specific rather than standardized, a patient who doesn't qualify for one trial may still be a strong candidate for a different one investigating the same disease. This is a case-by-case review, not a checklist that applies the same way across studies.

What a Trial Actually Costs

This is an area where being upfront about the limits of a general answer matters more than sounding precise.

• Sponsor-covered studies frequently absorb the cost of the investigational drug itself, since generating data is the sponsor's objective.

• Supportive care costs — hospitalization, imaging, standard-of-care components administered alongside the investigational therapy, and monitoring for side effects — are handled differently protocol to protocol. Some trials cover these; many do not.

• Boao Lecheng early access generally does not carry a research subsidy at all, since it isn't a study — patients are typically paying for the therapy and hospital care directly, though the zone's tariff and VAT exemptions on qualifying imported products can reduce the baseline cost of the drug or device itself.

We're not going to publish a single dollar figure for "what a clinical trial costs" here, because it depends entirely on the specific protocol, sponsor, and site — anyone telling you a fixed number before reviewing the actual trial's cost-sharing terms is getting ahead of what's actually knowable. A coordinator who has reviewed the specific protocol's terms can tell you what applies to a given study; a general estimate can't.

Which Hospitals Run Active Oncology Trials

Hospitals with documented trial activity and published outcome data include:

Hospital	City	Trial Focus
Ruijin Hospital, Shanghai	Shanghai	Hematology, CAR-T constructs, published outcome data
Sun Yat-sen University Cancer Center	Guangzhou	Nasopharyngeal, liver, and broader solid-tumor trials
Shanghai Changhai Hospital	Shanghai	Active clinical trials hub across multiple tumor types
Peking University Cancer Hospital	Beijing	National-level oncology research programs
Boao Super Hospital & Hope International Cancer Center	Qionghai, Hainan	Boao Lecheng early-access pathway (not standard trial enrollment)

All ChinaCureLink partner hospitals hold Grade 3A certification, and any CAR-T products used at commercial (non-trial) scale through our network are NMPA-approved. Trial-specific site authorization is separate from a hospital's general accreditation and is confirmed per study.

Understanding the Real Risk Profile

Experimental treatment access is a meaningful option for some patients — it is not a shortcut to a better outcome than approved therapy, and it shouldn't be framed that way.

• Early-phase data reflects a small, closely monitored patient group. Encouraging early results don't guarantee the same outcome at a larger scale or over a longer follow-up period.

• Novel constructs (allogeneic cells, new antigen targets, bispecifics) carry side-effect profiles that are still being characterized, unlike commercially approved CAR-T products, where cytokine release syndrome (CRS) and neurotoxicity (ICANS) management protocols are well established.

• Informed consent for a trial is its own document and conversation — separate from consent for standard treatment — and should be reviewed with your own oncologist at home where possible, not only with the treating trial team.

• There is no guaranteed outcome. Trials exist because the answer isn't known yet; that's the honest starting point for any conversation about enrolling in one.

How ChinaCureLink Supports Trial and Early-Access Cases

Navigating either pathway from outside China involves real coordination work: identifying which studies are actually open and accepting international patients right now, confirming protocol-specific eligibility against your pathology and treatment history, and understanding what a specific trial or Boao Lecheng pathway will and won't cover before you commit to travel.

Our clinical team reviews your case against currently open studies and relevant Boao Lecheng options, and — if you proceed — coordinates medical record translation, hospital communication, visa documentation, and logistics for the length of stay a given protocol requires. For the full process from first contact through post-treatment follow-up, see our 7-step process guide.

What Patients Say About ChinaCureLink & Medebound HEALTH

China CureLink operates under Medebound HEALTH — an internationally recognized healthcare navigation company incorporated in New York, with operations across North America and Asia-Pacific.

Rated 4.6 ⭐⭐⭐⭐⭐ at Trustpilot

Medebound HEALTH's online testimonials. Learn More

★★★★☆   Sarah Zhang  ·  Canada· Jul 2024  ·  Verified

“The interpreter during the video call was fantastic — super professional and answered all our questions clearly and quickly. The professor was also very patient and gave us detailed and honest guidance on our treatment options.”

★★★★★   Andrew Goh  ·  Singapore · Aug 2024  ·  Verified

“My first contact with Medebound was over a year ago. Jason has always been responsive, even when I wasn't ready to proceed. When I finally did, the consultation was seamlessly arranged and the specialist was outstanding.”

★★★★★   Daniel Wong  ·  Singapore · Aug 2024  ·  Verified

“I have dry eye and nothing seemed to be working, even with different medications. I heard about a medication from the U.S. that’s supposed to be really effective, but I didn’t want to try it without talking to a doctor first. MEDEBOUND connected me with a top ophthalmologist in the U.S. and it was so reassuring to get their expert advice.”

★★★★☆   Pongsakorn  ·  Thailand · Feb 2025  ·  Verified

“Kiki at Medebound is amazing — so professional and helpful! They got my video consultation with an MD Anderson expert set up super fast, within just 5 working days. I am so grateful for their support.”

Frequently Asked Questions

Can international patients enroll in cancer clinical trials in China?

Yes, though it's decided study-by-study rather than as a blanket policy. Some trials are designed with international arms or accept international patients who meet the protocol's criteria; others are limited to domestic enrollment. A case review against currently open, relevant studies is the only reliable way to know what's actually available for a specific diagnosis.

Is the Boao Lecheng zone the same as a clinical trial?

No. Boao Lecheng is a special administrative zone in Hainan where authorized hospitals can use drugs and devices already approved by the FDA or EMA but not yet approved by China's NMPA. It operates under Hainan's "urgent clinical need" rules, not a research protocol — and generally does not carry the cost subsidies that sponsor-funded trials often do.

How much does clinical trial enrollment cost in China?

It varies significantly by protocol. Sponsor-covered studies often provide the investigational drug at no cost, but hospitalization, monitoring, and standard-of-care components are handled differently trial to trial. There's no single figure that applies across studies — this needs to be confirmed against the specific protocol's terms.

What's the difference between a clinical trial and an approved therapy like commercial CAR-T?

An approved therapy, like the NMPA-approved CAR-T products already commercially available in China, has completed regulatory review based on established safety and efficacy data. A clinical trial is testing a therapy that hasn't completed that process yet — the data is still being generated, and outcomes are less predictable by definition.

Does China have solid tumor CAR-T available now, or is it still experimental?

Both, depending on the specific indication. In 2026, China's NMPA approved the world's first CAR-T therapy for a solid tumor (CLDN18.2-positive gastric/GEJ cancer), meaning that specific product is commercially available, not investigational. Other solid-tumor CAR-T constructs — for different antigens or cancer types — remain in active trials.

How do I know if a specific trial is legitimate?

Ask for the trial's ChiCTR or NMPA IND registration number, the sponsoring institution, the ethics committee approval, and any published interim data. A legitimate study will have documented ethics review and be findable in a public registry. Any program unable or unwilling to provide this should be treated with real caution.

References

1. China's NMPA Approves First CAR T-Cell Therapy for CLDN18.2+, HER2- Advanced Gastric/GEJ Adenocarcinoma — OncLive, 2026. https://www.onclive.com/view/china-s-nmpa-approves-first-car-t-cell-therapy-for-cldn18--2-her2-advanced-gastric-gej-adenocarcinoma

2. CARsgen Makes History as China Approves World's First CAR-T Therapy for Solid Tumors — Fierce Pharma, 2026. https://www.fiercepharma.com/pharma/carsgens-gastric-cancer-car-t-nabs-world-first-approval-china-checking-landmark-solid-tumor

3. Trends of Phase I Clinical Trials of New Drugs in Mainland China Over the Past 10 Years (2011–2020) — PMC, 2021. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718673/

4. Re-analysis of the current status of clinical trial registration in China (ChiCTR) — PMC, 2025. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11826807/

5. Hainan's Free Trade Port: Medical Tourism and the Development of Boao Lecheng Pilot Zone — HKTDC Research, 2025. https://research.hktdc.com/en/article/MTc1Njc2MDAyNQ

6. Early Market Access Approval for NMPA Unapproved Devices and Drugs in Boao, Hainan — ChinaMedDevice.com. https://chinameddevice.com/hainan-drugs-medical-devices/

About ChinaCureLink

ChinaCureLink helps patients across the world access the best cancer treatment at China's top hospitals, without the delays, language barriers, and administrative confusion that typically come with seeking care abroad.

We connect patients directly with China's top cancer hospitals, ensuring that from the first case submission through to treatment and follow-up, every step is guided, translated, and coordinated by a team experienced in cross-border patient care.

ChinaCureLink is proudly affiliated with Medebound HEALTH — an international medical concierge company headquartered in New York, specialized in securing premium second opinions from top US hospitals and specialists. With over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized as one of the leading patient access services across North America and the Asia-Pacific, bringing the same standard of expert care coordination to every patient we serve.

This article is for informational purposes only and does not constitute medical or financial advice. All treatment and trial-enrollment decisions should be made in consultation with a qualified oncologist who has reviewed your complete medical history and current diagnostic information, and confirmed against the specific protocol's terms with a coordinator.